Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2443]

$Patients with refractory metastatic colorectal cancer experience survival benefits with fruquintinib$

Patients with refractory metastatic colorectal cancer experience survival benefits with fruquintinib

Polygenic risk scores could improve colorectal cancer screening

Polygenic risk scores could improve colorectal cancer screening

Barrett’s oesophagus modeled in a human organ chip

Barrett’s oesophagus modeled in a human organ chip

ASCO 2023: Personalised vaccines may revolutionise cancer treatment

ASCO 2023: Personalised vaccines may revolutionise cancer treatment

Some intestinal T cells can hinder cancer immunotherapy, while others can enhance it

Some intestinal T cells can hinder cancer immunotherapy, while others can enhance it

ASCO 2023: Targeted therapy achieves responses across multiple cancer types with FGFR alterations

ASCO 2023: Targeted therapy achieves responses across multiple cancer types with FGFR alterations

ASCO 2023: Radiation can be safely omitted in select patients with locally advanced rectal cancer

ASCO 2023: Radiation can be safely omitted in select patients with locally advanced rectal cancer

ASCO 2023: Study may provide clues to treating colorectal cancer more effectively in younger patients

ASCO 2023: Study may provide clues to treating colorectal cancer more effectively in younger patients

ASCO 2023: For advanced, HER2-amplified bile duct cancers, antibody treatment trial shows promising results

ASCO 2023: For advanced, HER2-amplified bile duct cancers, antibody treatment trial shows promising results

ASCO 2023: Targeted therapy induces responses in HER2-amplified biliary tract cancer

ASCO 2023: Targeted therapy induces responses in HER2-amplified biliary tract cancer

More from ecancer